The partners will evaluate patients' responses to immunotherapeutic drugs, including PD-1 and PDL-1 inhibitors, based on bladder cancer subtypes.
According to the company, its approach allows for improved detection of EV-bound proteins and phosphoproteins, which it is using for biomarker discovery.
In urothelial cancer, the presence of a gene signature stemming from stromal cells seemed to interfere with anti-PD-1 drug response in tumors with infiltrating T-cells.
In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.
The Israeli firm recently announced the results of a multicenter study of its Bladder EpiCheck test in addition to netting €2.5 million in EU funding to develop a lung cancer assay.
A PCR-based analysis of nearly 700 cases picked up human papillomavirus or human polyomaviruses DNA in a fraction of urothelial bladder carcinoma tumors.
The company hopes to launch its first clinical cancer test within the next year, after spending the last several years conducting validation studies.
The researchers found that tumors expressing STAG2 as a biomarker are twice as likely to recur and progress toward muscle invasion and metastasis.
The firm has developed a new classifier for bladder cancer and continues to work with pharma companies in the lung cancer space.
In Science this week: environmental DNA can help in studies of marine animals, and more.
A genome-wide association study highlights a potential role for hair follicles in acne risk, according to New Scientist.
Newsday reports that breast cancer genetic testing guidelines for are out of date and may miss individuals.
In Cell this week: gene editing-based strategy to screen for immune system regulators, ancient plague patterns, and more.
Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.